Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

Yong Fang, Daniel J. McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P. Vellano, Yiling Lu, Yongsheng Li, Kang Jin Jeong, Zhiyong Ding, Jiyong Liang, Steven W. Wang, Hui Dai, Sanghoon Lee, Nidhi Sahni, Imelda Mercado-Uribe, Tae beom Kim, Ken Chen & 7 others Shiaw Yih Lin, Guang Peng, Shannon N. Westin, Jinsong Liu, Mark J. O'Connor, Timothy A. Yap, Gordon Mills

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We demonstrate that concurrent administration of poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors is effective in inhibiting tumor growth but poorly tolerated. Concurrent treatment with PARP and WEE1 inhibitors induces replication stress, DNA damage, and abrogates the G2 DNA damage checkpoint in both normal and malignant cells. Following cessation of monotherapy with PARP or WEE1 inhibitors, effects of these inhibitors persist suggesting that sequential administration of PARP and WEE1 inhibitors could maintain efficacy while ameliorating toxicity. Strikingly, while sequential administration mirrored concurrent therapy in cancer cells that have high basal replication stress, low basal replication stress in normal cells protected them from DNA damage and toxicity, thus improving tolerability while preserving efficacy in ovarian cancer xenograft and patient-derived xenograft models. Fang et al. show that sequential inhibition of PARP (PARPi) and WEE1 or ATR has antitumor efficacy similar to concurrent treatment but reduced toxicity due to the persistence of DNA damage on removal of PARPi and differences in basal replication stress between tumor and normal cells, respectively.

Original languageEnglish (US)
Pages (from-to)851-867.e7
JournalCancer Cell
Volume35
Issue number6
DOIs
StatePublished - Jun 10 2019

Fingerprint

DNA Damage
Poly(ADP-ribose) Polymerases
Heterografts
Neoplasms
Therapeutics
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors
Growth

Keywords

  • PARP inhibitor
  • replication stress
  • sequential therapy
  • WEE1 inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. / Fang, Yong; McGrail, Daniel J.; Sun, Chaoyang; Labrie, Marilyne; Chen, Xiaohua; Zhang, Dong; Ju, Zhenlin; Vellano, Christopher P.; Lu, Yiling; Li, Yongsheng; Jeong, Kang Jin; Ding, Zhiyong; Liang, Jiyong; Wang, Steven W.; Dai, Hui; Lee, Sanghoon; Sahni, Nidhi; Mercado-Uribe, Imelda; Kim, Tae beom; Chen, Ken; Lin, Shiaw Yih; Peng, Guang; Westin, Shannon N.; Liu, Jinsong; O'Connor, Mark J.; Yap, Timothy A.; Mills, Gordon.

In: Cancer Cell, Vol. 35, No. 6, 10.06.2019, p. 851-867.e7.

Research output: Contribution to journalArticle

Fang, Y, McGrail, DJ, Sun, C, Labrie, M, Chen, X, Zhang, D, Ju, Z, Vellano, CP, Lu, Y, Li, Y, Jeong, KJ, Ding, Z, Liang, J, Wang, SW, Dai, H, Lee, S, Sahni, N, Mercado-Uribe, I, Kim, TB, Chen, K, Lin, SY, Peng, G, Westin, SN, Liu, J, O'Connor, MJ, Yap, TA & Mills, G 2019, 'Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy', Cancer Cell, vol. 35, no. 6, pp. 851-867.e7. https://doi.org/10.1016/j.ccell.2019.05.001
Fang, Yong ; McGrail, Daniel J. ; Sun, Chaoyang ; Labrie, Marilyne ; Chen, Xiaohua ; Zhang, Dong ; Ju, Zhenlin ; Vellano, Christopher P. ; Lu, Yiling ; Li, Yongsheng ; Jeong, Kang Jin ; Ding, Zhiyong ; Liang, Jiyong ; Wang, Steven W. ; Dai, Hui ; Lee, Sanghoon ; Sahni, Nidhi ; Mercado-Uribe, Imelda ; Kim, Tae beom ; Chen, Ken ; Lin, Shiaw Yih ; Peng, Guang ; Westin, Shannon N. ; Liu, Jinsong ; O'Connor, Mark J. ; Yap, Timothy A. ; Mills, Gordon. / Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. In: Cancer Cell. 2019 ; Vol. 35, No. 6. pp. 851-867.e7.
@article{c9e08cd86a484013959a6667526fc039,
title = "Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy",
abstract = "We demonstrate that concurrent administration of poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors is effective in inhibiting tumor growth but poorly tolerated. Concurrent treatment with PARP and WEE1 inhibitors induces replication stress, DNA damage, and abrogates the G2 DNA damage checkpoint in both normal and malignant cells. Following cessation of monotherapy with PARP or WEE1 inhibitors, effects of these inhibitors persist suggesting that sequential administration of PARP and WEE1 inhibitors could maintain efficacy while ameliorating toxicity. Strikingly, while sequential administration mirrored concurrent therapy in cancer cells that have high basal replication stress, low basal replication stress in normal cells protected them from DNA damage and toxicity, thus improving tolerability while preserving efficacy in ovarian cancer xenograft and patient-derived xenograft models. Fang et al. show that sequential inhibition of PARP (PARPi) and WEE1 or ATR has antitumor efficacy similar to concurrent treatment but reduced toxicity due to the persistence of DNA damage on removal of PARPi and differences in basal replication stress between tumor and normal cells, respectively.",
keywords = "PARP inhibitor, replication stress, sequential therapy, WEE1 inhibitor",
author = "Yong Fang and McGrail, {Daniel J.} and Chaoyang Sun and Marilyne Labrie and Xiaohua Chen and Dong Zhang and Zhenlin Ju and Vellano, {Christopher P.} and Yiling Lu and Yongsheng Li and Jeong, {Kang Jin} and Zhiyong Ding and Jiyong Liang and Wang, {Steven W.} and Hui Dai and Sanghoon Lee and Nidhi Sahni and Imelda Mercado-Uribe and Kim, {Tae beom} and Ken Chen and Lin, {Shiaw Yih} and Guang Peng and Westin, {Shannon N.} and Jinsong Liu and O'Connor, {Mark J.} and Yap, {Timothy A.} and Gordon Mills",
year = "2019",
month = "6",
day = "10",
doi = "10.1016/j.ccell.2019.05.001",
language = "English (US)",
volume = "35",
pages = "851--867.e7",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

AU - Fang, Yong

AU - McGrail, Daniel J.

AU - Sun, Chaoyang

AU - Labrie, Marilyne

AU - Chen, Xiaohua

AU - Zhang, Dong

AU - Ju, Zhenlin

AU - Vellano, Christopher P.

AU - Lu, Yiling

AU - Li, Yongsheng

AU - Jeong, Kang Jin

AU - Ding, Zhiyong

AU - Liang, Jiyong

AU - Wang, Steven W.

AU - Dai, Hui

AU - Lee, Sanghoon

AU - Sahni, Nidhi

AU - Mercado-Uribe, Imelda

AU - Kim, Tae beom

AU - Chen, Ken

AU - Lin, Shiaw Yih

AU - Peng, Guang

AU - Westin, Shannon N.

AU - Liu, Jinsong

AU - O'Connor, Mark J.

AU - Yap, Timothy A.

AU - Mills, Gordon

PY - 2019/6/10

Y1 - 2019/6/10

N2 - We demonstrate that concurrent administration of poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors is effective in inhibiting tumor growth but poorly tolerated. Concurrent treatment with PARP and WEE1 inhibitors induces replication stress, DNA damage, and abrogates the G2 DNA damage checkpoint in both normal and malignant cells. Following cessation of monotherapy with PARP or WEE1 inhibitors, effects of these inhibitors persist suggesting that sequential administration of PARP and WEE1 inhibitors could maintain efficacy while ameliorating toxicity. Strikingly, while sequential administration mirrored concurrent therapy in cancer cells that have high basal replication stress, low basal replication stress in normal cells protected them from DNA damage and toxicity, thus improving tolerability while preserving efficacy in ovarian cancer xenograft and patient-derived xenograft models. Fang et al. show that sequential inhibition of PARP (PARPi) and WEE1 or ATR has antitumor efficacy similar to concurrent treatment but reduced toxicity due to the persistence of DNA damage on removal of PARPi and differences in basal replication stress between tumor and normal cells, respectively.

AB - We demonstrate that concurrent administration of poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors is effective in inhibiting tumor growth but poorly tolerated. Concurrent treatment with PARP and WEE1 inhibitors induces replication stress, DNA damage, and abrogates the G2 DNA damage checkpoint in both normal and malignant cells. Following cessation of monotherapy with PARP or WEE1 inhibitors, effects of these inhibitors persist suggesting that sequential administration of PARP and WEE1 inhibitors could maintain efficacy while ameliorating toxicity. Strikingly, while sequential administration mirrored concurrent therapy in cancer cells that have high basal replication stress, low basal replication stress in normal cells protected them from DNA damage and toxicity, thus improving tolerability while preserving efficacy in ovarian cancer xenograft and patient-derived xenograft models. Fang et al. show that sequential inhibition of PARP (PARPi) and WEE1 or ATR has antitumor efficacy similar to concurrent treatment but reduced toxicity due to the persistence of DNA damage on removal of PARPi and differences in basal replication stress between tumor and normal cells, respectively.

KW - PARP inhibitor

KW - replication stress

KW - sequential therapy

KW - WEE1 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85065764379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065764379&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2019.05.001

DO - 10.1016/j.ccell.2019.05.001

M3 - Article

VL - 35

SP - 851-867.e7

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -